ArticleClinical and translational allergy2025
The impact of repeated drug desensitisation on quality of life in drug hypersensitivity.
Article in Clinical and translational allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The impact of repeated drug desensitisation on quality of life in drug hypersensitivity.Clinical and translational allergy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMeasurement of disease-specific quality of life (QOL) is crucial in evaluating the effects of disease and response to treatment. Patients' efforts to avoid the responsible medication can have a negative impact on the QOL of patients with drug hypersensitivity reactions (DHRs). The Drug Hypersensitivity QOL Questionnaire (DrHy-Q) is the only specific tool measuring disease specific QOL in patients with DHRs.
objectiveTo evaluate the effect of repeated drug desensitisation on disease-specific QOL using the Turkish version of DrHy-Q in a prospective multicentre study.
methodsPatients scheduled to undergo repeated desensitisations with the same drug were included in the study. Baseline DrHy-Q scores were recorded for each patient prior to the commencement of the desensitisation procedure. DrHy-Q scores were then calculated following each desensitisation procedure.
resultsThe study included 111 patients with two or more desensitisations (age mean ± SD, years: 53.87 ± 11.36, F/M:94/17). The drugs most implicated in DHRs were chemotherapeutics (91 of 111 patients, 82%) followed by biologicals (16 of 111 patients, 14.4%). Before the desensitisation process, the median (min-max) pre-DrHy-Q score was 39 (16-74). The median (min-max) DrHy-Q scores after the first three desensitisation were 35 (19-69), 34 (15-68) and 35 (15-64), respectively. There was a statistically significant improvement in DrHy-Q scores after the first three desensitisation in comparison with baseline.
conclusionThe health-related disease-specific QOL of patients with hypersensitivity to drugs significantly improved after the first three, but not after subsequent drug desensitisations, as compared to baseline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.